Cesca Therapeutics Inc (KOOL) - NASDAQ
  • Jul. 16, 2013, 7:52 AM

    ThermoGenesis (KOOL) will merge with privately held TotipotentRx, a cell-based regenerative medicine company. KOOL will issue 12.491M shares worth some $18.6M to TotipotentRx. The deal is expected to close in Q4 and will be "transformative," in the words of KOOL CEO Matthew Plavan. (PR)

    | Jul. 16, 2013, 7:52 AM | 1 Comment
Company Description
Cesca Therapeutics, Inc. is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It is engaged in developing and manufacturing automated blood and bone marrow processing systems and companion disposable products that... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States